Sustained Focal Antitumor Activity of Bevacizumab in Recurrent Glioblastoma

Neurology - United States
doi 10.1212/wnl.0000000000000853
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors

Unknown

Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Addition of Lomustine for Bevacizumab-Refractory Recurrent Glioblastoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2014English

Bevacizumab and Chemotherapy for Recurrent Glioblastoma: A Single-Institution Experience

Neurology
Neurology
2009English

Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2016English

Erratum To: Single-Agent Bevacizumab Is an Effective Treatment in Recurrent Glioblastoma

Medical Oncology
MedicineCancer ResearchOncologyHematology
2015English

Single-Institution Retrospective Review of Patients With Recurrent Glioblastoma Treated With Bevacizumab in Clinical Practice

Health Science Reports
2019English

Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients With Recurrent Glioblastoma in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Increased Antitumor Activity of Bevacizumab in Combination With Hypoxia Inducible Factor-1 Inhibition

Molecular Cancer Therapeutics
Cancer ResearchOncology
2009English

Quantification of Edema Reduction Using Differential Quantitative T2 (DQT2) Relaxometry Mapping in Recurrent Glioblastoma Treated With Bevacizumab

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2011English

Bevacizumab for Recurrent Hemangioendothelioma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy